MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in
Hand Osteoarthritis
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today
announced that its licensing partner GSK has initiated a phase 2 clinical study
to investigate the effectiveness and safety of GSK3196165 (previously known as
MOR103) in patients with inflammatory hand osteoarthritis (HOA). GSK3196165 is a
monoclonal antibody against GM-CSF (granulocyte-macrophage colony-stimulating
factor) cytokine, a target molecule for a broad range of inflammatory diseases.
The antibody was discovered and engineered by MorphoSys using its HuCAL
technology and outlicensed to GSK in 2013.
The European multi-center phase 2 double-blind, placebo-controlled study will
investigate the efficacy and safety of subcutaneous injections of GSK3196165 in
40 adult subjects with inflammatory hand osteoarthritis. The main objective of
the study is to assess the efficacy potential of GSK3196165 on pain in
inflammatory HOA. Secondary objectives include the assessment of safety and
pharmacokinetics of GSK3196165.
Osteoarthritis is a condition that causes damage to the surface of joints in the
body leading to joint pain and stiffness. In some patients it can adversely
affect work and normal daily activities.
"We are delighted to see our licensing partner GSK moving GSK3196165 into a
clinical phase 2 study designed to assess its efficacy and safety in
inflammatory hand osteoarthritis, a chronic disease with high medical need",
commented Arndt Schottelius, Chief Development Officer of MorphoSys AG. "In
addition to an ongoing phase 2 study in rheumatoid arthritis, this is GSK's
second clinical study with GSK3196165 in a therapeutically highly relevant
indication. We are excited that our partner is further broadening the clinical
development program with this HuCAL antibody discovered by MorphoSys."
About GSK3196165 (MOR103)
In 2013, MorphoSys outlicensed MOR103 (now: GSK3196165) to GlaxoSmithKline
(GSK). Under the terms of the agreement, GSK assumed responsibility for all
subsequent development and commercialization activities of the drug candidate.
MorphoSys received an immediate upfront payment of EUR 22.5 million. On
achievement of certain developmental, regulatory, commercial and sales-based
milestones, MorphoSys will be eligible to receive additional payments from GSK
of up to EUR 423 million to total, in addition to tiered, double-digit royalties
on net sales.
GSK3196165 is a HuCAL-derived antibody against GM-CSF (granulocyte-macrophage
colony-stimulating factor) cytokine, a target molecule for a broad range of
inflammatory diseases. GSK is currently developing GSK3196165 in two clinical
trials in two indications - a phase 2b study in rheumatoid arthritis (initiated
in Q3 2015) and a phase 2a study in inflammatory hand osteoarthritis (started
now). MorphoSys has concluded a Phase 1 study in healthy volunteers, a phase
1/2 study in mild to moderate rheumatoid arthritis as well as a phase 1b study
in multiple sclerosis.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/2004259/739981.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#2004259]
Unternehmensinformation / Kurzprofil:
Datum: 18.04.2016 - 11:41 Uhr
Sprache: Deutsch
News-ID 464494
Anzahl Zeichen: 6258
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) in Hand Osteoarthritis"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
